The content on this site is intended for healthcare professionals only
Lung cancer is the most common cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for more than 85% of cases.
The current COVID-19 pandemic has introduced a number of difficulties for the management of patients with NSCLC.
Patients are at an increased risk of COVID-19 and its related complications, while the restrictions to daily life have also impacted appointment and treatment schedules and patients' mental health.
In this video, Dr Giuseppe Giaccone (Weill Cornell Medicine, New York City, USA) is joined by Dr Marina Garassino (Instituto Nazionale dei Tumori, Milan, Italy) and they discuss the management of the treatment of NSCLC patients during the COVID-19 pandemic.
(IT)
This programme has been developed by M3 (EU) and funded by an unrestricted grant from Pfizer. Pfizer has had no involvement or influence on the content of this programme.
Unlocking the potential of liquid biopsy applications in personalised care for older adults with cancer
New classification for identifying HR myeloma based on cytogenetic abnormalities
The case for global gender-neutral HPV vaccination
Tele-mentoring: Impact of project ECHO
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Gastro-intestinal endoscopy capacity in Nigeria: strengths and challenges
Colorectal cancer risk factors in Nigeria
Choosing Wisely to mitigate financial toxicity in cancer care in Africa
Redefining cancer research priorities in the emerging context of the COVID-19 pandemic
